Every earnings call for ADVENZYMES — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ADVENZYMES · 6 transcripts · Healthcare · latest Q4 FY26Revenue ₹203 cr (+22% YoY); EBITDA ₹63 cr (+39% YoY); EBITDA Margin 31.0%. Q4 FY26 Revenue from operations grew 22% YoY to ₹203.4 crores, marking the highest-ever quarterly revenue.
Read full transcript & analysisRevenue 1719 million (+2% YoY); EBITDA 494 million (−11% YoY); EBITDA Margin 29%. PAT grew 11% Y-o-Y to INR 432 million in Q3 FY26.
Read full transcript & analysisRevenue 1845 million (+26% YoY); EBITDA 601 million (+42% YoY); EBITDA Margin 33%. Consolidated revenue of INR 1,845 million, up 26% YoY.
Read full transcript & analysisRevenue 1859 million (+20% YoY); EBITDA 564 million (+10% YoY); EBITDA Margin 30%. Revenue of INR1,859 million, up 20% YoY and 11% QoQ.
Read full transcript & analysisRevenue 1672 million (+6% YoY); EBITDA 456 million (−18% YoY); EBITDA Margin 27%. FY25 total revenue grew by 2% to INR 6,369 million.
Read full transcript & analysisRevenue ₹169 cr (+5% YoY); EBITDA ₹55 cr (+3% YoY); EBITDA Margin 33.0%. Q3 FY25 Revenue of Rs. 169.1 crores, up 16% QoQ and 5% YoY.
Read full transcript & analysis